Bio-Techne Corporation (TECH)

Every figure this model derived for TECH, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 25,260,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-03-31
cash 209,819,000 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 688,050,000 AssetsCurrent 2026-03-31
current liabilities 153,278,000 LiabilitiesCurrent 2026-03-31
equity 2,085,304,000 StockholdersEquity 2026-03-31
interest expense 9,685,000 InterestExpenseNonoperating 2026-03-31
ocf 294,858,000 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 1,210,811,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-03-31
sbc 40,685,000 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up TECH on one particular measure came for.

RatioValue
cash operating margin20.09
current ratio5.99
current ratio reported4.49
deferred revenue growth19.1
dilution pct-0.66
ebit cagr-24.72
ebit yoy-50.53
fcf margin22.27
growth cv0.88
interest cover10.56
operating margin8.45
owner earnings margin18.91
revenue growth0.17
revenue growth per share0.83
roic3.89
rule of 408.61
sbc pct revenue3.36

What to be careful about

What this model itself distrusts about TECH's figures. Written by the derivation as it ran, not added afterwards.